14,990 Shares in Krystal Biotech, Inc. $KRYS Bought by Cim LLC

Cim LLC bought a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 14,990 shares of the company’s stock, valued at approximately $3,872,000.

Several other hedge funds also recently added to or reduced their stakes in the business. UMB Bank n.a. grew its position in Krystal Biotech by 34.6% during the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after purchasing an additional 37 shares during the period. Optimize Financial Inc lifted its holdings in shares of Krystal Biotech by 1.4% in the 4th quarter. Optimize Financial Inc now owns 2,855 shares of the company’s stock valued at $704,000 after buying an additional 40 shares during the period. Perigon Wealth Management LLC boosted its stake in shares of Krystal Biotech by 0.5% in the fourth quarter. Perigon Wealth Management LLC now owns 8,970 shares of the company’s stock worth $2,211,000 after buying an additional 41 shares during the last quarter. Regal Investment Advisors LLC boosted its stake in shares of Krystal Biotech by 1.0% in the fourth quarter. Regal Investment Advisors LLC now owns 4,360 shares of the company’s stock worth $1,075,000 after buying an additional 44 shares during the last quarter. Finally, Torray Investment Partners LLC boosted its stake in shares of Krystal Biotech by 0.4% in the first quarter. Torray Investment Partners LLC now owns 12,032 shares of the company’s stock worth $3,108,000 after buying an additional 47 shares during the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock opened at $363.28 on Thursday. The business has a 50 day simple moving average of $337.61 and a two-hundred day simple moving average of $295.22. Krystal Biotech, Inc. has a 12 month low of $130.50 and a 12 month high of $382.54. The stock has a market capitalization of $10.71 billion, a P/E ratio of 48.57 and a beta of 0.50.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.45 by $0.38. The company had revenue of $116.36 million for the quarter, compared to analysts’ expectations of $112.11 million. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. As a group, research analysts anticipate that Krystal Biotech, Inc. will post 7.31 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on KRYS. TD Cowen lifted their price target on Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Weiss Ratings lowered Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, July 1st. Bank of America raised their price objective on shares of Krystal Biotech from $364.00 to $396.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Citigroup increased their price target on shares of Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Finally, Evercore restated an “outperform” rating and set a $300.00 price target on shares of Krystal Biotech in a research report on Tuesday, May 5th. Ten research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $360.67.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, EVP John Charles Thomas sold 1,000 shares of the stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $347.27, for a total value of $347,270.00. Following the completion of the sale, the executive vice president owned 1,000 shares in the company, valued at approximately $347,270. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the completion of the sale, the insider owned 1,378,155 shares of the company’s stock, valued at approximately $424,623,337.05. The trade was a 1.78% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 26,642 shares of company stock worth $8,243,923 over the last 90 days. 13.10% of the stock is currently owned by company insiders.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.